A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

Lutetium-177 Market Lutetium-177 Market Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier ...

从药融云数据库获悉，2024年5月20日，Immunome宣布完成对 Atreca的抗体和相关资产的收购，通过此次收购，Immunome获得28款抗体，拟用于ADC药物研发。 Immunome 是一家成立于 2008 ...

图片来源：摄图网前不久，在诺华的上半年业绩中，除重磅心衰药ENTRESTO与重磅自免新药Cosentyx的惊人销量外，PRC领域的重磅新药Pluvicto也是其半年报中业绩增长最快的品种之一，其销量的突破也让PRC疗法进入了更多公司的BD标的行列。 ...

ANSTO congratulated the Peter Macallum Cancer Centre led team, who recently reported the remarkable results of late-stage ...

A new type of prostate cancer therapy that is used only in late-stage treatment where conventional therapy has failed has ...

Rotorua cancer patient Daniel Hazelwood has spent $36,000 on private prostate cancer treatment this year. Without it, “I’d be ...

证券之星消息，截至2024年9月20日收盘，金鹰股份(600232)报收于4.45元，下跌1.98%，换手率0.61%，成交量2.23万手，成交额1000.62万元。 9月20日的资金流向数据方面，主力资金净流出146.81万元，占总成交额14.67 ...

The University of Missouri Research Reactor (MURR) has successfully delivered its first batch of no-carrier-added lutetium-177 (NCA Lu-177) for cancer treatment. The weekly shipments are being ...

乳腺癌是女性最常见的恶性肿瘤之一。国家癌症中心最新发布的全国癌症报告显示，我国被诊断出乳腺癌的女性超过了35万，位列我国女性新发恶性肿瘤人数第二位；同年因乳腺癌去世的女性有7.5万，位列我国女性恶性肿瘤死亡人数第五位 ...

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.